Logotype for Exelixis Inc

Exelixis (EXEL) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Exelixis Inc

Q3 2026 earnings summary

2 Nov, 2026

Executive summary

  • Q3 2026 revenue rose 10% YoY to $658.7M; GAAP net income was $218.1M and diluted EPS was $0.85.

  • Cabozantinib growth and broad zanzalintinib development underpin oncology franchise expansion, alongside disciplined R&D investment and shareholder returns.

Financial highlights

  • Q3 net product revenue was $604.9M, up 11% YoY; collaboration revenue was $53.8M, including $51.8M in cabozantinib royalties.

  • GAAP operating expenses were $390.3M: R&D $209.5M and SG&A $154.6M; SG&A growth reflected personnel, clinical, marketing and legal costs.

  • Non-GAAP net income was $240.2M and diluted EPS was $0.94, excluding stock-based compensation net of tax.

  • Q3 operating income was $268.4M versus $236.5M YoY; GAAP net income was $218.1M versus $193.6M.

Outlook and guidance

  • FY 2026 revenue guidance remains $2.500B–$2.550B, including net product revenue of $2.300B–$2.350B; guidance excludes potential zanzalintinib CRC approval and launch revenue.

  • FY 2026 COGS guidance is ~4% of net product revenue; R&D guidance is $825M–$875M and SG&A is $575M–$625M.

  • FY 2026 effective tax-rate guidance fell to 16%–18% from 21%–23%.

  • STELLAR-304 top-line results are expected in Q1 2027; positive results could support a second zanzalintinib NDA.

  • STELLAR-303 NDA review was extended; the updated PDUFA target date is March 3, 2027.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Exelixis